Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christie J Lau

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JCO Precision Oncology|February 1, 2022
Does Testing Error Underlie Liquid Biopsy Discordance?Cloud P Paweletz, Christie J Lau, Geoffrey R Oxnard
Gigascience|August 22, 2024
TooManyCellsInteractive: A visualization tool for dynamic exploration of single-cell dataConor Klamann, Christie J Lau, Javier Ruiz-Ramírez, et al.
Oral Oncology|July 27, 2019
Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancerGlenn J Hanna, Christie J Lau, Umair Mahmood, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical SamplesDeepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.
Molecular Cancer Therapeutics|November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent ResistanceMagda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
The Journal of Clinical Investigation|November 5, 2020
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockadeKartik Sehgal, Andrew Portell, Elena V Ivanova, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JCO Precision Oncology|February 1, 2022
Does Testing Error Underlie Liquid Biopsy Discordance?Cloud P Paweletz, Christie J Lau, Geoffrey R Oxnard
Gigascience|August 22, 2024
TooManyCellsInteractive: A visualization tool for dynamic exploration of single-cell dataConor Klamann, Christie J Lau, Javier Ruiz-Ramírez, et al.
Oral Oncology|July 27, 2019
Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancerGlenn J Hanna, Christie J Lau, Umair Mahmood, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2019
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical SamplesDeepa Rangachari, Ciric To, Jason E Shpilsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2019
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockadeMohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, et al.
Molecular Cancer Therapeutics|November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent ResistanceMagda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
The Journal of Clinical Investigation|November 5, 2020
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockadeKartik Sehgal, Andrew Portell, Elena V Ivanova, et al.
Pageof 1